Tirzepatide – Laboratory-Grade. Verified Purity. 1 Vial Pack
High-purity tirzepatide single-vial research units provide academic and industrial investigators with verified, analytical-grade material for dual GIP and GLP-1 receptor studies. Supplied exclusively for in vitro assays and preclinical models, every lot undergoes rigorous analytical testing to guarantee reproducible data across cellular and animal research systems.
Quick answer
High-purity tirzepatide single-vial research units provide academic and industrial investigators with verified, analytical-grade material for dual GIP and GLP-1 receptor studies. Supplied exclusively for in vitro assays and preclinical models, every lot undergoes rigorous analytical testing to guarantee reproducible data across cellular and animal research systems.
Key takeaways
- A laboratory-grade [tirzepatide](/research-peptides/tirzepatide) 1 vial pack is a single, lyophilized research-grade unit containing a synthetic 39-amino-acid peptide engineered for dual activation of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
- [Tirzepatide](/research-peptides/tirzepatide) is a chemically synthesized polypeptide analog with an empirical formula of C225H348N48O68 and a molecular weight of approximately 4813.53 Da.
- Preclinical evaluations in rodent and non-human primate models highlight the synergism of dual GIP/GLP-1 agonism over mono-selective incretin targeting.
- In metabolic research, comparing single, dual, and triple receptor agonists is critical for elucidating differential intracellular signaling pathways.
Direct Answer & Technical Overview: Tirzepatide 1-Vial Research Pack
A laboratory-grade tirzepatide 1 vial pack is a single, lyophilized research-grade unit containing a synthetic 39-amino-acid peptide engineered for dual activation of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Verified for sequence accuracy, purity, and low endotoxin content, this single-vial format allows research institutions to conduct pilot assays, validation protocols, and controlled titration studies without committing to bulk procurement.
To maintain assay validity and minimize research variability, PX1 Research provides fully characterized tirzepatide reagents accompanied by lot-specific certificates of analysis (COAs). Investigators seeking analytical consistency rely on these standardized single vials across diverse experimental models. You can explore our full range of reference reagents in our all-peptides catalog or consult our research library hub for technical documentation.
Molecular Structure and Dual Agonist Mechanism of Action
Tirzepatide is a chemically synthesized polypeptide analog with an empirical formula of C225H348N48O68 and a molecular weight of approximately 4813.53 Da. Its primary sequence is modeled upon the native GIP peptide structure, but incorporates strategic amino acid substitutions including C-terminal amidation and a C20 fatty diacid moiety attached via a glutamic acid linker to the Lys20 residue. This structural lipid modification enables non-covalent albumin binding, substantially prolonging the peptide's elimination half-life in preclinical animal models.
Biochemically, tirzepatide operates as an unbalanced dual agonist. In vitro receptor binding assays demonstrate that tirzepatide possesses native-like affinity for the GIP receptor, while exhibiting approximately five-fold lower affinity for the GLP-1 receptor compared to endogenous GLP-1. Despite lower GLP-1 receptor affinity, signaling assays show robust biased agonism, favoring cyclic adenosine monophosphate (cAMP) generation over beta-arrestin recruitment. This unique receptor engagement profile reduces GLP-1 receptor internalization, promoting sustained signaling kinetics during cellular incubation.
Preclinical Findings: In Vitro and Animal Model Data
Preclinical evaluations in rodent and non-human primate models highlight the synergism of dual GIP/GLP-1 agonism over mono-selective incretin targeting. In diet-induced obesity (DIO) mouse models, administration of research-grade tirzepatide demonstrated dose-dependent reductions in cumulative food intake, body weight, and total fat mass superior to single GLP-1 receptor activation. Studies investigating pancreatic islet biology show that co-activation of GIP and GLP-1 pathways enhances glucose-dependent insulin secretion while blunting glucagon secretion during hyper-glycemic clamp procedures.
Furthermore, in vitro hepatic and adipocyte cell line models suggest that tirzepatide signaling modulates lipid metabolic pathways, downregulating lipogenic gene expression (such as SREBP1c and FAS) while upregulating markers of mitochondrial biogenesis and fatty acid oxidation. These metabolic shifts provide a mechanistic foundation for ongoing investigation into tissue-specific insulin sensitivity, energy expenditure, and ectopic lipid deposition.
Comparative Analysis: Tirzepatide vs. Semaglutide and Retatrutide
In metabolic research, comparing single, dual, and triple receptor agonists is critical for elucidating differential intracellular signaling pathways. Tirzepatide represents a major evolutionary step from mono-selective agents by co-targeting GIP and GLP-1 receptors, offering distinct signaling profiles compared to first- and second-generation peptides.
For instance, mono-selective GLP-1 receptor agonists such as Semaglutide 5mg operate exclusively through GLP-1 pathways, establishing baseline incretin response curves in metabolic models. In contrast, multi-receptor agonists expand this pathway activation: tirzepatide incorporates dual GIP/GLP-1 activation, while triple agonists like Retatrutide 10mg add glucagon receptor (GCGR) activity to the matrix. To review structural mechanisms and comparative binding affinities across these peptide classes, scientists can reference our detailed guide on gip glp1 dual agonists.
Analytical Purity Verification: HPLC, Mass Spectrometry, and Endotoxin Control
Assay reproducibility in laboratory settings hinges entirely on raw material purity and chemical identity. PX1 Research enforces strict quality assurance parameters for every batch of Tirzepatide 10mg single vials. Analytical validation protocols include Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chromatographical purity exceeding 99.0%, ensuring the complete absence of truncation sequences and synthesis side-products.
Exact mass identity is verified through Electrospray Ionization Mass Spectrometry (ESI-MS), matching the observed molecular weight against theoretical values. Because lipopolysaccharide contamination can confound immunological and metabolic culture assays, every lot undergoes rigorous Limulus Amebocyte Lysate (LAL) chromogenic endotoxin testing to guarantee levels strictly below <0.01 EU/mg. Investigators interested in analytical methodology can read our background overview on endotoxin testing peptide purity.
US Manufacturing Standards and Lot Traceability
All PX1 Research peptides are manufactured in US-based, ISO 17025 accredited and GMP-compliant facilities. From initial solid-phase peptide synthesis (SPPS) through counter-ion exchange and final lyophilization, every step is executed under cleanroom environments to protect product integrity.
Each single-vial package features an explicit lot number tied directly to its third-party analytical COA. Researchers can verify raw MS spectra, HPLC chromatograms, and quantitative endotoxin values prior to initiating experimental procedures. Orders placed Monday through Friday ship same-day from our California and Arizona logistics hubs, minimizing transit delays for time-sensitive laboratory schedules.
Laboratory Reconstitution Protocols and Handling Requirements
Tirzepatide is supplied as a sterile, lyophilized cake intended solely for laboratory reconstitution prior to in vitro or in vivo animal administration. For standard working solutions, researchers utilize sterile target diluents such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4).
Reconstitution should be conducted within a certified laminar flow hood. Diluent should be allowed to run gently down the inner glass wall of the vial rather than sprayed directly onto the peptide cake, followed by gentle swirling until complete dissolution is achieved. Vortexing or vigorous mechanical agitation must be avoided, as high shear forces can induce peptide aggregation or structural denaturation. For precise volumetric calculations, consult our peptide reconstitution calculator guide.
Storage Conditions, Stability, and Handling Precautions
Upon receipt, lyophilized tirzepatide vials should be stored in a freezer at -20°C or -80°C, protected from light and moisture. Under desiccated, sub-zero conditions, the lyophilized peptide remains stable for up to 24 months without measurable chemical degradation.
Once reconstituted into aqueous solution, aliquots should be used immediately or stored at 2°C to 8°C for short-term experimentation (up to 7 days) or sub-aliquoted and frozen at -80°C for extended use. Repeated freeze-thaw cycles must be strictly avoided to prevent peptide chain cleavage and activity loss. Note that all tirzepatide reagents provided by PX1 Research are strictly designated for laboratory research use only and are not intended for human or veterinary diagnostic or therapeutic applications.
Institutional Procurement and Wholesale Availability
While the 1 vial pack is ideal for pilot projects, assay optimization, and initial binding studies, PX1 Research also supports large-scale academic and enterprise research initiatives. Principal investigators and laboratory managers requiring high-volume supplies or custom synthesis batches can register for institutional purchasing via our wholesale portal.
Wholesale accounts receive direct access to dedicated account management, bulk pricing tiers, custom vial sizing, and scheduled recurring shipments from our US fulfillment centers. Every bulk batch maintains the exact same analytical rigor, ISO 17025 testing standards, and COA documentation as our individual research packs.
Frequently Asked Questions
What is the purity level of PX1 Research tirzepatide 1 vial packs?
Every lot of tirzepatide is verified via RP-HPLC to meet or exceed 99.0% chemical purity, with exact mass confirmed through ESI-MS.
How is endotoxin testing performed on tirzepatide single vials?
Endotoxin levels are quantified using a chromogenic LAL (Limulus Amebocyte Lysate) assay, ensuring levels remain strictly below <0.01 EU/mg to prevent cell culture toxicity or immune activation in animal models.
What diluent should be used for reconstituting tirzepatide for in vitro research?
Laboratory reconstitution typically utilizes sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory protocols or sterile 0.9% Sodium Chloride / PBS (pH 7.4) for immediate cellular assays.
How should reconstituted tirzepatide solutions be stored?
Reconstituted liquid solutions should be kept at 2°C to 8°C for short-term use (up to 7 days). For longer storage, solutions should be divided into single-use aliquots and kept at -80°C to prevent degradation from freeze-thaw cycles.
Where are PX1 Research tirzepatide vials manufactured and shipped from?
All PX1 Research peptides are synthesized in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona, with same-day dispatch for orders placed M–F.
What molecular targets does tirzepatide engage in preclinical models?
Tirzepatide acts as a dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
Can tirzepatide single vials be ordered for non-institutional pilot studies?
Tirzepatide single vials are available to qualified university, biotech, and independent laboratory investigators for legitimate in vitro and preclinical research applications.
Is tirzepatide approved for human clinical use or administration?
No. Tirzepatide supplied by PX1 Research is a research chemical provided strictly for laboratory, in vitro, and animal experimentation. It is not for human or veterinary use.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.